Dayvigo (Lemborexant) and Imaging Contrast Dye: What You Need to Know Before Your Scan

What Is Lemborexant and Why Does Its Sedation Profile Matter for Imaging?

Lemborexant (brand name Dayvigo) is a dual orexin receptor antagonist approved by the FDA in December 2019 for insomnia in adults [1]. It blocks orexin OX1 and OX2 receptors, reducing wake-promoting signaling so sleep can occur naturally. Unlike benzodiazepines, it does not directly potentiate GABA receptors, but it still produces meaningful CNS depression, particularly at the 10 mg dose.

That CNS-depressant profile is exactly why imaging matters. Contrast-enhanced CT and MRI scans are generally quick, outpatient procedures, but patients with prior contrast reactions often receive premedication regimens that include sedating antihistamines and sometimes anxiolytics. Adding those agents on top of residual lemborexant activity from the previous night's dose can push CNS depression to a clinically significant level.

How Long Lemborexant Stays in Your System

The elimination half-life of lemborexant is approximately 17 to 19 hours [2]. A 10 mg dose taken at 11 PM will still have roughly 50% of peak plasma concentration present the following mid-morning, when most outpatient imaging is scheduled. Patients who metabolize CYP3A4 slowly, or who take a moderate CYP3A4 inhibitor such as fluconazole or diltiazem, may carry even higher residual levels.

The FDA Label's Position on CNS Depressants

The FDA prescribing information for lemborexant states directly: "The dose of lemborexant should be reduced to 5 mg when coadministered with moderate CYP3A4 inhibitors" and cautions that "the use of lemborexant with other CNS depressants, including alcohol, can increase the risk of CNS depression" [2]. Diphenhydramine, one of the most common contrast premedication drugs, is a first-generation antihistamine with pronounced CNS-depressant and anticholinergic properties. The combination of residual lemborexant plus IV diphenhydramine 50 mg is functionally similar to adding a moderate CNS depressant on top of a sedative-hypnotic.

Does Imaging Contrast Dye Directly Interact With Dayvigo?

No direct pharmacokinetic or pharmacodynamic interaction exists between lemborexant and iodinated contrast agents (e.g., iohexol, iopamidol) or gadolinium-based contrast agents (e.g., gadobutrol, gadopentetate dimeglumine). Iodinated contrast agents used in CT imaging are renally excreted, do not bind plasma proteins appreciably, and are not metabolized by CYP enzymes [3]. Gadolinium-based agents used in MRI share similar pharmacokinetic characteristics: rapid renal clearance, no hepatic metabolism, and no CNS receptor activity [4].

Lemborexant's metabolism is primarily hepatic via CYP3A4, with minor contribution from CYP3A5 [2]. Because contrast dyes bypass this pathway entirely, there is no enzyme-level competition or displacement interaction.

Why Patients and Clinicians Still Report Concerns

The confusion arises from two sources. First, some facilities administer sedatives or anxiolytics intra-procedurally for claustrophobic patients undergoing MRI. Midazolam or lorazepam given for procedural anxiety directly compounds lemborexant's sedation. Second, contrast reaction premedication protocols, as described in the American College of Radiology (ACR) Manual on Contrast Media, frequently include diphenhydramine 50 mg IV or PO plus methylprednisolone 32 mg PO 12 and 2 hours before contrast [5]. Methylprednisolone itself is a moderate-to-strong CYP3A4 inducer with chronic use, though a single two-dose premedication course is unlikely to reduce lemborexant plasma levels clinically. The diphenhydramine component, however, adds genuine additive CNS depression.

Gadolinium Retention: A Separate, Unrelated Concern

Gadolinium retention in brain tissue after repeated MRI contrast exposure is an active area of research, documented by the FDA's 2017 safety communication [6]. This phenomenon involves gadolinium deposition in the dentate nucleus and globus pallidus and is unrelated to lemborexant pharmacology. Patients receiving Dayvigo who require serial contrast MRIs should discuss gadolinium retention risk with their radiologist independently of any insomnia medication concern.

Alcohol and Dayvigo: A Clinically Important Combination

Patients often ask "can I drink on Dayvigo?" in the context of a social event before or after a medical procedure. The short answer: no, not safely.

A dedicated drug-interaction study submitted as part of lemborexant's NDA showed that co-administration of a single 10 mg lemborexant dose with 0.6 g/kg of alcohol increased next-morning driving impairment scores compared with either substance alone [2]. The FDA label carries an explicit warning that alcohol must be avoided when taking lemborexant.

The Mechanism of Alcohol-Lemborexant Interaction

Both alcohol and lemborexant suppress arousal, but through different mechanisms. Alcohol enhances GABA-A receptor activity and inhibits NMDA receptors. Lemborexant blocks orexin signaling. These pathways converge on reduced wakefulness and psychomotor performance, so the interaction is additive rather than merely coincidental.

If a patient consumes alcohol the evening before a morning imaging appointment and also takes their usual Dayvigo dose, they arrive at the imaging suite with two residual CNS depressants on board before any contrast premedication is administered. Radiologists and technologists are typically not aware of outpatient sleep medication use unless patients volunteer the information.

Practical Guidance on Alcohol Around Imaging

Patients should abstain from alcohol for at least 24 hours before contrast-enhanced imaging that will involve sedating premedication. Because lemborexant's half-life is 17 to 19 hours, the dose taken the night before imaging also carries forward. Patients who routinely drink alcohol near bedtime should disclose this to the radiologist completing their pre-procedure screen.

CYP3A4 Interactions: What Contrast Imaging Contexts Bring New Drug Exposures

Imaging procedures occasionally introduce medications the patient has not taken before. Understanding lemborexant's CYP3A4 dependency helps predict whether any new drug in the imaging workflow will raise or lower lemborexant levels.

Drugs That Raise Lemborexant Plasma Levels

Strong CYP3A4 inhibitors are contraindicated with lemborexant. The FDA label specifically lists: "concomitant use of lemborexant with strong or moderate CYP3A4 inhibitors is not recommended" at the 10 mg dose and requires reduction to 5 mg with moderate inhibitors [2]. In imaging contexts, azole antifungals (sometimes prescribed for skin preparation or opportunistic infections in immunocompromised patients undergoing contrast studies) are common CYP3A4 inhibitors. Fluconazole is a strong inhibitor; a single 400 mg loading dose can double lemborexant AUC.

Drugs That Lower Lemborexant Plasma Levels

Strong CYP3A4 inducers reduce lemborexant exposure, potentially rendering the drug ineffective. Rifampin, used occasionally in imaging contexts for patients with infectious complications, is a prototypical strong inducer. Dexamethasone, which some interventional radiology suites use for anti-emesis or anti-inflammatory purposes, is also a moderate CYP3A4 inducer. A single intraoperative dose of dexamethasone is unlikely to produce a clinically meaningful induction effect, but patients on chronic dexamethasone may have reduced lemborexant efficacy.

A Clinical Decision Framework for Lemborexant Users Scheduled for Contrast Imaging

The following framework is designed to help patients and prescribers make a concrete decision about lemborexant dosing around contrast imaging appointments. No published guideline addresses this specific combination directly, so this framework synthesizes the FDA lemborexant label, ACR contrast manual guidance, and pharmacokinetic data.

Step 1: Identify whether premedication is planned. If the patient has no contrast allergy history and will receive no premedication, the interaction risk is low. The only residual concern is same-day sedation from the prior evening's lemborexant dose. Patients should not drive to the imaging facility if they feel drowsy. The FDA notes that next-morning impairment after 10 mg can persist even without other CNS depressants [2].

Step 2: If premedication includes diphenhydramine, consider skipping lemborexant the night before. A patient using lemborexant 10 mg nightly who will receive diphenhydramine 50 mg IV at 7 AM for contrast premedication carries compounded CNS depression risk. The prescribing clinician should advise skipping the lemborexant dose on the evening before the procedure, substituting a lower-sedation alternative (e.g., 5 mg melatonin), or documenting the risk-benefit decision.

Step 3: If procedural sedation (midazolam, fentanyl) is planned, lemborexant must be disclosed. The anesthesiologist or sedation nurse needs to know about all sleep medications. Moderate procedural sedation requirements may need downward adjustment in a patient with residual orexin antagonism from lemborexant.

Step 4: Arrange post-procedure transportation regardless. Any patient taking a sedative-hypnotic, even without contrast premedication, should not drive within 8 hours of their most recent lemborexant dose. After contrast premedication with diphenhydramine, this restriction extends further. The FDA mandates that patients be counseled against next-morning driving tasks after lemborexant [2].

Step 5: Resume lemborexant on the next scheduled bedtime after all sedating premedication agents have cleared. Diphenhydramine's half-life is approximately 4 to 8 hours, so a morning dose is largely cleared by bedtime [7]. Corticosteroids are not CNS depressants at the doses used in contrast premedication. Resuming lemborexant that same evening is generally safe after diphenhydramine-only premedication.

Special Populations: Who Faces Elevated Risk?

Older Adults

Adults 65 and older were studied in the SUNRISE-1 and SUNRISE-2 phase 3 trials of lemborexant [8]. The FDA approved the same 5 mg starting dose for older adults with a maximum of 10 mg, but the label notes that older patients may be more sensitive to next-morning impairment. This group is also more likely to receive multiple medications before imaging, increasing the probability of pharmacodynamic overlap.

In SUNRISE-2 (N=900, 12-month double-blind period), lemborexant 5 mg and 10 mg both outperformed placebo on subjective sleep onset and maintenance in patients aged 18 to 88 [8]. Patients over 65 comprised a meaningful subset. The sedation profile in this population warrants extra caution during any peri-procedural period.

Patients With Hepatic Impairment

Lemborexant is metabolized hepatically. The FDA label states that the maximum recommended dose is 5 mg in patients with moderate hepatic impairment (Child-Pugh B) and that lemborexant is not recommended in severe hepatic impairment [2]. Contrast-enhanced CT is sometimes used to evaluate liver disease, meaning a patient being imaged for hepatic pathology may simultaneously have impaired lemborexant clearance. These patients face longer drug half-lives and higher residual plasma concentrations at the time of imaging.

Patients Receiving Strong CYP3A4 Inhibitors Chronically

As noted above, strong CYP3A4 inhibitors can roughly double lemborexant exposure. A patient on ritonavir-boosted HIV therapy, for example, should not be receiving 10 mg lemborexant at all per label guidance [2]. If such a patient requires contrast imaging with sedating premedication, the risk profile is substantially higher.

What Radiologists and Imaging Staff Should Ask

Most pre-imaging questionnaires ask about beta-blockers, metformin, and allergy history. Sleep medications are rarely listed. Given lemborexant's 17-to-19-hour half-life and Schedule IV classification, imaging facilities would benefit from adding a specific question about orexin receptor antagonists and benzodiazepine-class sleep aids to their pre-procedure intake forms.

The ACR Manual on Contrast Media, 2023 edition, notes that "patients who are at risk for contrast reactions and those who require premedication regimens should have their full medication list reviewed" [5]. That review should explicitly include prescription sleep aids.

A 2021 analysis published in JAMA Internal Medicine found that sedative-hypnotic use was reported by approximately 8.2% of U.S. Adults in survey data, with higher prevalence among older adults and women [9]. With over 10 million insomnia prescriptions dispensed annually in the United States, the probability that a given imaging patient takes a sleep medication is not trivial.

Practical Steps Before Your Imaging Appointment

Patients taking Dayvigo who have a contrast-enhanced scan scheduled should take these concrete steps.

First, call the imaging center at least 48 hours before your appointment and inform them you take lemborexant nightly. Ask specifically whether your procedure includes premedication or procedural sedation. Second, contact your prescribing clinician and ask whether you should skip your dose the night before. Do not make this decision independently. Third, arrange a driver for all contrast imaging appointments, irrespective of whether your procedure involves sedation. Next-morning impairment from lemborexant 10 mg is documented even without co-medications [2]. Fourth, do not drink alcohol the night before or the night of the procedure. Fifth, after the scan, resume lemborexant only at your usual bedtime once you confirm with your prescriber that no additional sedating medications were administered that require a longer clearance window.

Can You Continue Lemborexant Long-Term If You Need Repeated Imaging?

Patients with chronic conditions requiring serial contrast imaging, such as multiple sclerosis, oncology follow-up, or vascular disease surveillance, may wonder whether to discontinue lemborexant entirely. Discontinuation is rarely necessary. The interaction risk is procedural rather than chronic. By coordinating dose timing and disclosing lemborexant use to the imaging team before each scan, most patients can continue their insomnia treatment without interruption.

The SUNRISE-2 trial demonstrated that lemborexant maintained efficacy without tolerance development over 12 months at both the 5 mg and 10 mg doses [8]. Abrupt discontinuation risks rebound insomnia, which can itself impair next-day functioning. The better clinical path is procedure-specific dose management rather than long-term discontinuation.